In the present study, we have designed and synthesized a series of 1-benzyl-2-methyl-3-indolylmethylene barbituric acid analogs (7a-7h) and 1-benzyl-2-methyl-3-indolylmethylene thiobarbituric acid analogs (7 i-7 l) as nucleophosmin 1 (NPM1) inhibitors and have evaluated them for their anti-cancer activity against a panel of 60 different human cancer cell lines. Among these analogs 7 i, 7 j, and 7 k demonstrated potent growth inhibitory effects in various cancer cell types with GI50 values <2 μM. Compound 7 k exhibited growth inhibitory effects on a sub-panel of six leukemia cell lines with GI50 values in the range 0.22-0.35 μM. Analog 7 i also exhibited GI50 values <0.35 μM against three of the leukemia cell lines in the sub-panel. Analogs 7 i, 7 j, 7 k and 7 l were also evaluated against the mutant NPM1 expressing OCI-AML3 cell line and compounds 7 k and 7 l were found to cause dose-dependent apoptosis (AP50 = 1.75 μM and 3.3 μM, respectively). Compound 7k also exhibited potent growth inhibition against a wide variety of solid tumor cell lines: that is, A498 renal cancer (GI50 = 0.19 μM), HOP-92 and NCI-H522 lung cancer (GI50 = 0.25 μM), COLO 205 and HCT-116 colon cancer (GI50 = 0.20 and 0.26 μM, respectively), CNS cancer SF-539 (GI50 = 0.22 μM), melanoma MDA-MB-435 (GI50 = 0.22 μM), and breast cancer HS 578T (GI50 = 0.22 μM) cell lines. Molecular docking studies suggest that compounds 7 k and 7 l exert their anti-leukemic activity by binding to a pocket in the central channel of the NPM1 pentameric structure. These results indicate that the small molecule inhibitors 7 i, 7 j, 7 k, and 7 l could be potentially developed into anti-NPM1 drugs for the treatment of a variety of hematologic malignancies and solid tumors.
In the present study, we have designed and synthesized a series of 1-benzyl-2-methyl-3-indolylmethylene barbituric acid analogs (n class="Chemical">7a-7h) and 1-benzyl-2-methyl-3-indolylmethylene thiobarbituric acid analogs (7 i-7 l) as nucleophosmin 1 (NPM1) inhibitors and have evaluated them for their anti-cancer activity against a panel of 60 different humancancer cell lines. Among these analogs 7 i, 7 j, and 7 k demonstrated potent growth inhibitory effects in various cancer cell types with GI50 values <2 μM. Compound 7 k exhibited growth inhibitory effects on a sub-panel of six leukemia cell lines with GI50 values in the range 0.22-0.35 μM. Analog 7 i also exhibited GI50 values <0.35 μM against three of the leukemia cell lines in the sub-panel. Analogs 7 i, 7 j, 7 k and 7 l were also evaluated against the mutant NPM1 expressing OCI-AML3 cell line and compounds 7 k and 7 l were found to cause dose-dependent apoptosis (AP50 = 1.75 μM and 3.3 μM, respectively). Compound 7k also exhibited potent growth inhibition against a wide variety of solid tumor cell lines: that is, A498 renal cancer (GI50 = 0.19 μM), HOP-92 and NCI-H522 lung cancer (GI50 = 0.25 μM), COLO 205 and HCT-116colon cancer (GI50 = 0.20 and 0.26 μM, respectively), CNS cancer SF-539 (GI50 = 0.22 μM), melanomaMDA-MB-435 (GI50 = 0.22 μM), and breast cancer HS 578T (GI50 = 0.22 μM) cell lines. Molecular docking studies suggest that compounds 7 k and 7 l exert their anti-leukemic activity by binding to a pocket in the central channel of the NPM1 pentameric structure. These results indicate that the small molecule inhibitors 7 i, 7 j, 7 k, and 7 l could be potentially developed into anti-NPM1 drugs for the treatment of a variety of hematologic malignancies and solid tumors.
Authors: Guido Marcucci; Krzysztof Mrózek; Michael D Radmacher; Ramiro Garzon; Clara D Bloomfield Journal: Blood Date: 2010-11-02 Impact factor: 22.113
Authors: Diana M Mitrea; Christy R Grace; Marija Buljan; Mi-Kyung Yun; Nicholas J Pytel; John Satumba; Amanda Nourse; Cheon-Gil Park; M Madan Babu; Stephen W White; Richard W Kriwacki Journal: Proc Natl Acad Sci U S A Date: 2014-03-10 Impact factor: 11.205
Authors: Konjeti R Sekhar; Yerramreddy Thirupathi Reddy; Penthala Narsimha Reddy; Peter A Crooks; Amudhan Venkateswaran; William Hayes McDonald; Ling Geng; Soumya Sasi; Robert P Van Der Waal; Joseph L Roti Roti; Kenneth J Salleng; Girish Rachakonda; Michael L Freeman Journal: Clin Cancer Res Date: 2011-08-30 Impact factor: 12.531
Authors: Y Thirupathi Reddy; Konjeti R Sekhar; Nidhish Sasi; P Narsimha Reddy; Michael L Freeman; Peter A Crooks Journal: Bioorg Med Chem Lett Date: 2009-11-22 Impact factor: 2.823
Authors: Konjeti R Sekhar; Mouadh Benamar; Amudhan Venkateswaran; Soumya Sasi; Narsimha R Penthala; Peter A Crooks; Stephen R Hann; Ling Geng; Ramesh Balusu; Tarek Abbas; Michael L Freeman Journal: Int J Radiat Oncol Biol Phys Date: 2014-07-08 Impact factor: 7.038
Authors: Maroof K Zafar; Leena Maddukuri; Amit Ketkar; Narsimha R Penthala; Megan R Reed; Sarah Eddy; Peter A Crooks; Robert L Eoff Journal: Biochemistry Date: 2018-01-30 Impact factor: 3.162
Authors: Joseph K Box; Nicolas Paquet; Mark N Adams; Didier Boucher; Emma Bolderson; Kenneth J O'Byrne; Derek J Richard Journal: BMC Mol Biol Date: 2016-08-24 Impact factor: 2.946
Authors: Emilie Darrigues; Edward H Zhao; Annick De Loose; Madison P Lee; Michael J Borrelli; Robert L Eoff; Deni S Galileo; Narsimha R Penthala; Peter A Crooks; Analiz Rodriguez Journal: Int J Mol Sci Date: 2021-10-03 Impact factor: 5.923